Italy Radiotherapy Market Report 2022 to 2030

Italy Radiotherapy Market Analysis

$ 3999

By 2030, it is anticipated that the Italy Radiotherapy Market will reach a value of $255 Mn from $166 Mn in 2022, growing at a CAGR of 5.5% during 2022-2030. The Radiotherapy Therapeutics Market in Italy is dominated by a few domestic players such as Oncology Systems Limited, IORT Technologies, and Elekta Italia. The radiotherapy market in Italy is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Italian radiotherapy is increasing on account of the rise in cancer cases in the country.

ID: IN10ITPH043 CATEGORY: Pharmaceuticals GEOGRAPHY: Italy AUTHOR: Dr. Vishwa Modhia

Buy Now

Italy Radiotherapy Market Analysis Summary

By 2030, it is anticipated that the Italy Radiotherapy Market will reach a value of $255 Mn from $166 Mn in 2022, growing at a CAGR of 5.5% during 2022-30.

Italy is a high-income, developed country located in Southern Europe comprising the boot-shaped Italian peninsula and several islands including Sicily and Sardinia. In Italy, it is expected that roughly 377,000 new cases of malignant tumors will be diagnosed, with approximately 195,000 males and nearly 182,000 females. Every day, 1,030 people in Italy are diagnosed with cancer. Geographic analyses of cancer frequency in Italy reveal significant North-South discrepancies.

In Italy, the proportion of radiotherapy cost to total cancer care spending was 5.4 %. In Italy, $564 Mn was spent on radiotherapy. In Italy, the proportion of radiation spending to total healthcare expenditure was 0.36 %. Italy's government spends 9.6 % of its GDP on healthcare in 2020.

Italy Radiotherapy Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Italy has the highest 5-year survival rate in the European Union, at 54% for men and 63% for women. Cancer-related mortality and incidence instances are increasing in Italy. Cancer is the leading cause of death among Italians aged 30-69. Cancer claimed the lives of 180,085 people in Italy in 2017, accounting for 27.7 % of all fatalities that year, with 100,123 men and 79,962 women dying. Tobacco use is the leading cause of lung cancer in Italy, accounting for 85 to 90 % of cases. The industrial sector is still highly recognised in Italy. These aspects could boost Italy Radiotherapy Market.

Market restraints

Despite the fact that Italy has a developed healthcare system, funding for specialised research is limited. This can make securing the essential funds for cancer research and development challenging. The budget for radiation in Italy is determined by the number of treatments or activities performed. These factors may deter new entrants into the Italy Radiotherapy Market.

Competitive Landscape

Key Players

Elekta Italia: Elekta is a Swedish company that provides radiation therapy and radiosurgery equipment and software. Elekta Italia is the Italian subsidiary of the company and provides sales, service, and support for its products in Italy
Varian Medical Systems Italia: Varian is an American company that produces medical devices and software for the treatment of cancer and other medical conditions. Varian Medical Systems Italia is the Italian subsidiary of the company and provides sales, service, and support for its products in Italy
IBA Dosimetry Italia: IBA Dosimetry is a Belgian company that provides dosimetry solutions for radiation therapy. IBA Dosimetry Italia is the Italian subsidiary of the company and provides sales, service, and support for its products in Italy
IORT Technologies: IORT Technologies is an Italian company that provides intraoperative radiation therapy solutions for the treatment of cancer. The company develops and manufactures a range of devices and systems that deliver targeted radiation therapy during surgery
General Electric (GE) Healthcare Italia: GE Healthcare is an American multinational conglomerate that provides medical devices, diagnostics, and healthcare services. GE Healthcare Italia is the Italian subsidiary of the company and provides sales, service, and support for their medical devices and software used in radiotherapy
Oncology Systems Limited (OSL) Italia: OSL is a UK-based company that provides equipment, software, and services for radiation therapy

Recent Notable Updates

January 2023: Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) in Udine, Italy, has completed 100 treatments with GammaPodTM, a brand-new stereotactic radiotherapy system specifically designed for breast cancer, and is nearing publication of the first structured study gathering data for this first phase of the trial.

Healthcare Policies and Reimbursement Scenarios

In Italy, radiotherapy is regulated and reimbursed by the Italian National Health Service (Servizio Sanitario Nazionale, SSN). The SSN provides free healthcare to all Italian citizens and legal residents, including radiotherapy services. The regulation of radiotherapy in Italy is overseen by the Italian Ministry of Health, which establishes guidelines and protocols for the use of radiotherapy in the treatment of cancer and other medical conditions. The SSN also provides reimbursement for certain types of advanced radiotherapy technologies, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT). AIFA intervenes in the governance of pharmaceutical expenditure by negotiating the price of medicinal products and managing the National Pharmaceutical Formulary (NFP).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Radiotherapy Segmentation

By Type (Revenue, USD Billion):

External Beam Radiation Therapy
Linear Accelerators
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
?Tomotherapy
Proton Therapy
Cyclotron
?Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Radiation Therapy
?Others

?By Technology (Revenue, USD Billion):

External Beam Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Stereotactic Radiation Therapy (SRT)
3D Conformal Radiation Therapy (3D-CRT)
Particle Therapy
Internal Beam Radiotherapy
Brachytherapy
High-Dose Rate Brachytherapy
Low-Dose Rate Brachytherapy
Image-Guided Brachytherapy
Pulse-Dose Rate Brachytherapy
Systemic Radiation Therapy
Intravenous Radiotherapy
Oral Radiotherapy?

By Application (Revenue, USD Billion):

Breast Cancer
Cervical Cancer
Colon and rectum Cancers
Stomach Cancer
Lung Cancer
Prostate Cancer
Skin Cancer
Liver Cancer
Other types of cancer

By End User (Revenue, USD Billion):

Hospitals
Radiotherapy Centers & Ambulatory Surgery Centers
?Cancer Research Institutes

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.